title: Sodium hydrosulfide prevents hypoxia-induced pulmonary arterial hypertension in broilers.
abstract: 1. The aim of the study was to determine if H(2)S is involved in the development of hypoxia-induced pulmonary hypertension in broilers, a condition frequently observed in a variety of cardiac and pulmonary diseases. 2. Two-week-old broilers were reared under normoxic conditions or exposed to normobaric hypoxia (6 h/day) with tissue levels of H(2)S adjusted by administering sodium hydrosulfide (NaHS, 10 µmol/kg body weight/day). Mean pulmonary arterial pressure, right ventricular mass, plasma and tissue H(2)S levels, the expression of cystathionine-β-synthase (CSE) and vascular remodeling were determined at 35 d of age. 3. Exposure to hypoxia-induced pulmonary arterial hypertension was characterized by elevated pulmonary pressure, right ventricular hypertrophy and vascular remodeling. This was accompanied by decreased expression of CSE and decreased concentrations of plasma and tissue H(2)S. 4. Hypoxia-induced pulmonary hypertension was significantly reduced by administration of NaHS but this protective effect was largely abolished by D, L-propargylglycerine, an inhibitor of CSE. 5. The results indicate that H(2)S is involved in the development of hypoxia-induced pulmonary hypertension. Supplementing NaHS or H(2)S could be a strategy for reducing hypoxia-induced hypertension in broilers.
authors.affiliation: Key State Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, P.R. China. bio2046@hotmail.com
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: B K
authors.initials: BK
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Liu
authors.forename: W
authors.initials: W
authors.lastname: Nie
authors.forename: J M
authors.initials: JM
authors.lastname: Yuan
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.forename: Y M
authors.initials: YM
authors.lastname: Guo
mesh_terms: D000818:Animals; D001201:Ascites / Q000188:drug therapy / Q000209:etiology; D015153:Blotting, Western / Q000662:veterinary; D002645:Chickens; D003541:Cystathionine beta-Synthase / Q000378:metabolism*; D003542:Cystathionine gamma-Lyase / Q000378:metabolism; D065627:Familial Primary Pulmonary Hypertension; D005990:Glycerol / Q000031:analogs & derivatives / Q000494:pharmacology*; D006862:Hydrogen Sulfide / Q000097:blood / Q000378:metabolism*; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000662:veterinary*; D017380:Hypertrophy, Right Ventricular / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000662:veterinary*; D000860:Hypoxia; D008297:Male; D011201:Poultry Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction / Q000662:veterinary; D013053:Spectrophotometry / Q000662:veterinary; D013440:Sulfides / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D013440:Sulfides; D003541:Cystathionine beta-Synthase; D003542:Cystathionine gamma-Lyase; C025451:sodium bisulfide; D005990:Glycerol; D006862:Hydrogen Sulfide